Physician profile
Charles A Powell
NPI 1922176072
$653,950.32
in general payments reported to CMS, 2019-2025
10 companies · $122K in 2025
The $122K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $40K · 2021: $56K · 2022: $113K · 2023: $127K · 2024: $110K · 2025: $122K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $357K · Travel and Lodging: $742 · Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $356,896.00 |
| Travel and Lodging | $742.40 |
| Food and Beverage | $514.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $586,217.51 | 2019-2025 | Enhertu, Datroway |
| Astrazeneca Uk Limited | $21,100.00 | 2020-2022 | |
| Biontech Se | $14,236.00 | 2023-2025 | |
| Seagen INC. | $11,437.50 | 2023 | |
| Eisai INC. | $6,867.50 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $6,204.31 | 2019-2025 | Tagrisso, Fasenra |
| E.R. Squibb & Sons, L.L.C. | $2,925.00 | 2021-2023 | |
| Ethicon INC. | $2,525.00 | 2023 | Prolene, Vicryl |
| Pfizer INC. | $2,437.50 | 2023-2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.